Skip to content

Press

Portfolio-Press Releases
Cerevance Doses First Patient in Pivotal Phase 3 ARISE Trial of Solengepras for Treatment of Parkinson’s Disease
November 18, 2024 Nov 18, 2024
Portfolio-Press Releases
ReCode Therapeutics Announces Additional Funding from the Cystic Fibrosis Foundation to Accelerate Development of Novel Gene Correction Therapeutics to Treat Cystic Fibrosis
November 18, 2024 Nov 18, 2024
Portfolio-Press Releases
Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers
November 11, 2024 Nov 11, 2024
Portfolio-Press Releases
Ensoma Unveils Three Programs Leveraging In Vivo Hematopoietic Stem Cell Engineering Platform to Target Genetic, Immune and Oncological Diseases
November 5, 2024 Nov 5, 2024
Portfolio-Press Releases
Ensoma Appoints Accomplished Deal Maker Jon Garen as Chief Corporate Development and Business Officer
October 28, 2024 Oct 28, 2024
Portfolio-Press Releases
Nido Biosciences Announces Orphan Drug Designation for Lead Clinical Candidate to Treat Spinal and Bulbar Muscular Atrophy
October 22, 2024 Oct 22, 2024
Portfolio-Press Releases
Cerevance Announces Publication of Positive Phase 2 Results of Solengepras for the Treatment of Parkinson’s Disease in eClinical Medicine
October 21, 2024 Oct 21, 2024
Portfolio-Press Releases
Cerevance Achieves Second Milestone in Research Collaboration with Merck
October 8, 2024 Oct 8, 2024
Portfolio-Press Releases
ReCode Announces Two Key Additions to Scientific Advisory Board
October 1, 2024 Oct 1, 2024
Portfolio-Press Releases
ReCode Therapeutics Doses First Patient in Phase 1b Clinical Study of RCT2100 for the Treatment of Cystic Fibrosis
September 26, 2024 Sep 26, 2024